News

Nasdaq

NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and ...

ZÜRICH, SWITZERLAND / ACCESSWIRE / December 3, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (NLS), a biopharmaceutical company, is pleased to share preclinical data demonstrating the ...

Synthetic receptors could offer path to disease-resistant crops

Researchers at RIKEN have discovered and engineered an ancient plant immune receptor, dubbed SCORE that recognizes cold-shock proteins in most pathogens.
Morningstar

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases

Ingelheim, Germany, and Princeton, New Jersey, USA, August 18 2025 – Boehringer Ingelheim and Palatin Technologies, Inc., (OTCQB: PTNTD), a biopharmaceutical company developing first-in-class ...